WINSTON Business Summary

Winston Medical Supply Co., Ltd. (6817.TWO) is a Taiwan-based pharmaceutical manufacturer specializing in the research, development, and commercialization of generic drugs, health supplements, and medical aesthetics. The company generates revenue through a vertically integrated model encompassing the production and sale of PIC/S GMP-certified western medicines, with primary business segments divided into ophthalmic preparations (eye drops and ointments), oral solids (tablets and capsules), hormone-based treatments, and topical medications. Winston distinguishes itself through a dominant market share in Taiwan’s sterile ophthalmic sector and a growing export business targeting Southeast Asian markets, including Thailand and Malaysia. It competes directly with domestic peers such as Syngen Biotech Co., Ltd. (8279.TWO), Nang Kuang Pharmaceutical Co., Ltd. (1752.TW), and SYN-TECH Chem. & Pharm. Co., Ltd. (1777.TWO), positioning itself as a specialized leader in high-barrier sterile manufacturing and hormone therapy. Founded in 1975 and headquartered in Tainan City, the company is currently led by Chairman Sen-Tien Tsai, a prominent medical figure and former Superintendent of the Ministry of Health and Welfare Tainan Hospital, and CEO Yu-Cheng Wang, who has overseen the firm’s strategic operations since 2010. The leadership team is supported by CFO Hsin-Wen Chang, who manages the group’s financial health and capital allocation. A pivotal moment in the company’s governance occurred in 2014 when Medigen Biotechnology Corp (3176.TWO) became the largest institutional shareholder, integrating Winston into a broader life sciences ecosystem. The board of directors maintains a strong focus on international regulatory compliance, leveraging its PIC/S GMP and ISO 22716 certifications to secure OEM/ODM contracts with global pharmaceutical partners.